Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


PM Opens High Tech Biotech Laboratories

Prime Minister Opens High Tech Biotech Laboratories

Virionyx Corporation Will Develop AIDS Drug at New Facility

Manukau City, Auckland (August 1, 2003) – The Prime Minister, the Right Honourable Helen Clark, today opens Virionyx Corporation’s state-of-the-art biopharmaceutical laboratory facility in Manukau City.

In the new laboratory, Virionyx will continue the development of its biotherapeutic treatment for late-stage AIDS patients, plus other drugs and antibody treatments for a range of viruses.

The company has developed a proprietary process for the treatment of viruses from which its first therapeutic, PEHRG214, a passive immunotherapy for HIV, was designed.

The therapeutic last year successfully completed a United States Federal Drug Agency (FDA) approved Phase I clinical trial at Beth Israel Deaconess Medical Centre at Harvard Medical School in Boston.

Currently, it is undergoing a multi-dose Phase I/II clinical trial at Harvard in which 40 HIV patients are being injected twice weekly with PEHRG214.

The therapeutic has shown under laboratory conditions that it is capable of killing the AIDS virus.

The internationally recognised cancer and AIDS specialist conducting the independent trials Harvard, Dr Bruce Dezube, has commented it “demonstrates early evidence of antiviral activity, even in anti-retroviral experienced individuals”.

Today’s opening ceremony at Virionyx’s new facility, will be attend by a number of local dignitaries, including Manukau City Mayor Sir Barry Curtis, local MP Honourable Taito Phillip Field, representatives from Manukau City Council and Enterprising Manukau development agency, plus company shareholders and staff. 2/…

Virionyx has moved to Manukau from smaller research facilities in Penrose. The move has allowed the company to build a PC3 laboratory, which can handle viruses in containment. As a result, Virionyx has recently transferred to New Zealand the viriology/cell biology technology developed by one of it its scientists, Dr Lisa Williams. This work was being undertaken by Dr Williams at the Westmead Millennium Institute in Sydney.

Ultimately, the new premises will include a full-scale production facility in which drugs and antibody treatments for a range of viruses, including PEHRG214, will be manufactured.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>


Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>